Alzheimer’s disease has had a long-running public identity crisis. For decades, it’s been introduced at parties as
“the amyloid plaque disease,” occasionally bringing its plus-one, “tau tangles,” and then leaving early because
honestlynobody wants to talk about neurodegeneration over chips and salsa.
But new research suggests something surprisingly physical may be doing a lot of the day-to-day damage:
swellingnot just the kind doctors spot on an MRI as “fluid,” but swelling inside nerve-cell wiring that
can jam the brain’s communication network. Meanwhile, newer Alzheimer’s drugs that reduce amyloid can modestly slow
decline in early diseaseyet some of them can also cause a different kind of brain swelling as a side effect.
Confusing? A little. Important? Absolutely. Let’s unpack what “swelling” means in Alzheimer’s, why it may matter
more than we realized, and how today’s newest treatments (and tomorrow’s) could fit into the picture.
Why “Swelling” Is Suddenly in the Alzheimer’s Spotlight
Swelling as a symptom-maker, not just a bystander
Alzheimer’s has always been described as a slow-motion brain traffic jam: proteins misfold, clump, and disrupt
normal function over many years. But one of the puzzles has been this: amyloid plaques alone don’t always match
up neatly with symptoms. Some people have lots of plaques with minimal symptoms, while others have severe
cognitive decline with less plaque burden than you’d expect.
Researchers at Yale reported evidence that amyloid plaques can trigger a specific downstream problem:
spheroid-shaped swellings along axonsthe long “cables” neurons use to send signals. Each plaque may
affect hundreds of nearby axons, and those swellings can blunt electrical signal transmission between brain regions.
In this view, it’s not just the plaque sitting there like a rock in a river; it’s the ripple effect that matters.
Here’s the key detail that makes neuroscientists lean forward in their chairs: those axonal swellings appear tied to
a pileup of lysosomes, the cell’s recycling and waste-processing compartments. If lysosomes clog up,
it’s like a city’s trash trucks all getting stuck in one neighborhoodsoon nothing moves the way it should.
Meet PLD3: a protein with unfortunate timing
The Yale team also implicated a lysosomal protein called PLD3. In mouse models, reducing PLD3 in
neurons decreased axonal swelling and helped normalize conduction along axons. That doesn’t mean we have a “PLD3
pill” tomorrow, but it does suggest a plausible target for therapies focused on restoring cellular cleanup and
preventing swelling-related signal failureeven if plaques remain.
Translation: if amyloid plaques are the match, swelling could be the smoke that’s actually choking the room.
And targeting the smoke might help people breathe easier, sooner.
Neuroinflammation: when the brain’s immune system won’t clock out
“Swelling” is also closely tied to neuroinflammation. The brain has immune-like cells (microglia)
and support cells (astrocytes) that react to injury, infection, and abnormal proteins. In Alzheimer’s, that response
can become chronic, releasing inflammatory signals that worsen synaptic function, damage neurons, and potentially
contribute to tissue-level swelling or edema in certain contexts.
Many scientists now describe Alzheimer’s as a messy collaboration between amyloid, tau, inflammation, vascular
changes, and synaptic lossnot a single-villain story. Swelling may be a common “output” of those processes:
swelling in axons, swelling around vessels, swelling in glial responses, and (in some treatments) swelling visible
on imaging.
What’s Happening in the Brain: Amyloid, Tau, and the “Tipping Point” Theory
To understand why swelling might matter, it helps to revisit the classic Alzheimer’s frameworkbriefly, because you
didn’t come here for a dry textbook recap. (You came for clarity. And possibly mild sarcasm.)
Amyloid plaques: the sticky buildup between neurons
Beta-amyloid is a naturally occurring protein fragment. In Alzheimer’s disease, it can accumulate into clumps
(plaques) between neurons. These plaques are one of the signature pathologic hallmarks seen in Alzheimer’s brains,
along with tau tangles.
Tau tangles: when internal scaffolding turns into a knot
Tau is normally involved in stabilizing internal neuron structure. In Alzheimer’s, abnormal tau changes form
tangles inside neurons. Evidence suggests that as amyloid builds to a “tipping point,” tau pathology may spread
more rapidly through memory-related networks.
Loss of connections: the real heartbreak
While plaques and tangles get the headlines, what correlates strongly with symptoms is the
loss of synapses and neural connectivity. And that’s where the swelling story becomes especially
interesting: axonal swellings could directly disrupt connectivity, creating functional “dropouts” in the brain’s
communication gridpotentially explaining why cognition can decline even when plaque volume itself doesn’t map
perfectly to symptoms.
New Drugs May HelpBut First, a Reality Check (and a Safety Check)
The newest FDA-approved disease-modifying Alzheimer’s treatments focus on reducing amyloid in the brain. The key
idea is straightforward: lower amyloid plaque burden in early disease, slow clinical decline. The reality is more
nuanced: benefits are generally modest, treatment requires ongoing monitoring, and risksespecially brain swelling
and bleedingare real.
Lecanemab (Leqembi): slowing decline in early Alzheimer’s
Lecanemab is an amyloid beta-directed antibody approved for treating Alzheimer’s disease in people
with mild cognitive impairment or mild dementia due to Alzheimer’s (in other words,
early symptomatic disease). In a major phase 3 trial, lecanemab reduced amyloid markers and led to
moderately less cognitive and functional decline over about 18 months compared with placebo.
This matters because “moderately less decline” is not a curebut it can translate into real-life time:
more months of recognizing loved ones, managing daily tasks, or staying independent. For many families, that’s not a
rounding error; it’s a gift.
But lecanemab comes with important risks, particularly ARIA:
amyloid-related imaging abnormalities. ARIA can involve localized brain swelling (ARIA-E) and/or
small areas of bleeding (ARIA-H). Many cases are asymptomatic and resolve, but serious and rarely fatal events have
occurred. That’s why MRI monitoring is a built-in part of treatmentnot optional, not a “nice to have.”
Donanemab (Kisunla): another anti-amyloid option
Donanemab is another antibody treatment for early symptomatic Alzheimer’s, approved by the FDA in
July 2024. It also targets amyloid plaques and showed slowing of clinical decline in a large phase 3 program.
Like lecanemab, it carries a boxed warning for ARIA, and appropriate patient selection plus MRI monitoring are
critical.
One practical point families learn quickly: these drugs aren’t a simple prescription you pick up with shampoo and
toothpaste. They’re a whole processdiagnosis confirmation (usually amyloid testing), infusion or injection plans,
monitoring schedules, and ongoing cognitive follow-up.
Important: “Swelling” can mean two different things
Here’s where the headlines can mislead people. When you read “swelling may be the root cause,” that’s usually
referring to microscopic swelling inside neural wiringlike axonal spheroids tied to lysosome
dysfunction. When you read about Alzheimer’s drugs causing “brain swelling,” that often refers to
ARIA-E, which is visible on MRI as edema or fluid-related change.
They’re not the same phenomenoneven though they share a word and both can disrupt brain function. Think of it like:
one is a traffic jam inside the cable lines; the other is construction flooding near the highway. Both can be bad,
but they happen for different reasons and are handled differently.
Could Brain Swelling Actually Be a Clue That Treatment Is Working?
In a twist that feels like it was written by a screenwriter who enjoys emotional whiplash, some recent analyses
suggest ARIA-E may sometimes appear in regions where amyloid is being cleared more aggressively. In other words, the
side effect could overlap with the treatment’s footprint. That doesn’t make ARIA “good,” and it definitely doesn’t
mean anyone should chase it. It means biology is complicated, and the brain does not read our press releases.
Regulators and clinicians have responded to safety signals by refining monitoring recommendations. The FDA has
communicated about earlier MRI monitoring for patients on lecanemab to help detect ARIA soonerbecause timing
matters when the rare severe cases tend to show up early in treatment.
The practical takeaway for patients and caregivers: if you’re considering anti-amyloid therapy, choose a care team
that treats ARIA monitoring like the main event, not a footnote. Ask about MRI timing, symptom watchlists, genetic
risk factors (like APOE variants), and what happens if ARIA is detected.
If Swelling Is a Root Cause, What Would “Anti-Swelling” Alzheimer’s Treatments Look Like?
If axonal swelling and lysosome dysfunction are central drivers of symptoms (even partly), future treatments could
expand beyond “clear plaques” to “restore the cell’s ability to stay unclogged.” That might include:
-
Targets like PLD3 or other lysosome-related regulators that influence organelle buildup and axonal
spheroids. -
Neuroinflammation modulators aimed at keeping microglia and astrocytes from staying stuck in a
chronic inflammatory loop. -
Vascular and blood-brain barrier support, because vessel “leakiness” and impaired clearance can
intensify inflammation and edema-like changes. -
Clearance pathway optimization, such as improving waste disposal systems and fluid movement in the
brain (a hot area of research, especially around sleep and glymphatic function).
The best-case future is not one “miracle drug,” but a layered strategy: identify Alzheimer’s early, reduce amyloid
burden where appropriate, calm harmful inflammation, protect connectivity, and keep neurons’ housekeeping systems
running efficiently. Like maintaining a house: you don’t just remove one leaky pipe; you also fix the mold,
reinforce the foundation, and stop leaving wet towels on the floor.
Who Might Benefit From Today’s New Alzheimer’s Drugsand Who Should Be Cautious?
Most current disease-modifying anti-amyloid therapies are designed for early Alzheimer’s disease:
people with mild symptoms and confirmed amyloid pathology. They are not indicated for advanced dementia.
That’s not a moral judgment; it’s how the trial evidence and safety data line up.
Key questions clinicians typically address
- Stage: Is this mild cognitive impairment or mild Alzheimer’s dementia?
-
Confirmation: Is Alzheimer’s pathology confirmed via amyloid PET, CSF biomarkers, or validated
blood testing pathways? -
Safety profile: What’s the risk of ARIA based on imaging findings, medication use (especially
anticoagulants), and genetic factors? - Logistics: Can the person reliably attend infusions/injections, MRIs, and follow-ups?
- Goals: What does “slowing decline” mean for this person and family in real terms?
If you’re reading this for a loved one, the best “first step” is often not a drug decisionit’s a diagnostic
clarity decision. Get a thorough workup. Rule out reversible causes. Confirm whether Alzheimer’s pathology is truly
the driver. Then, and only then, weigh treatment options.
Beyond Medication: What Actually Helps Families Right Now
Even in 2026, the most effective Alzheimer’s care is still a combination of medical treatment, safety planning, and
day-to-day support. Families who do best (and by “best” I mean “less chaos, more dignity”) often focus on:
1) Early planning while decision-making is still strong
Legal and financial planning isn’t glamorous, but neither is trying to do it during a crisis. Families who tackle
advance directives, power of attorney, and living arrangements early reduce stress later.
2) Cognitive support that’s actually usable
Sticky notes are fine. So are shared calendars, medication organizers, visual routines, and “one place for keys.”
The goal is not to treat your loved one like a toddler; it’s to reduce unnecessary friction.
3) Brain-healthy habits that support function
Managing cardiovascular risks, staying physically active, sleeping well, and maintaining social connection won’t
“cure” Alzheimer’s. But these habits support brain resilience and can improve quality of life. They’re also
something families can do immediatelyno insurance prior authorization required.
Real-World Experiences: What the “Swelling Story” Feels Like (500+ Words)
The science of swelling is fascinating in journals, but families live it in ordinary moments: the missed turn on a
familiar drive, the repeated question asked with genuine surprise each time, the sudden anger that feels out of
character, the quiet panic when bills don’t make sense anymore.
One common experience caregivers describe is the emotional whiplash of an Alzheimer’s diagnosis in the early stage.
On paper it can look “mild”the person still jokes, still dresses themselves, still remembers old stories. Yet
something is clearly changing: short-term memory evaporates, multi-step tasks fall apart, and stress tolerance
shrinks. When researchers talk about axonal swelling disrupting electrical signals between brain regions, caregivers
often nod without knowing the term, because the behavior matches the idea: it’s as if the brain’s internal Wi-Fi is
cutting in and out.
Families considering newer anti-amyloid drugs often describe the process as both hopeful and exhausting. Hopeful,
because “slowing decline” finally sounds like medicine has something concrete to offer. Exhausting, because the path
includes amyloid confirmation tests, discussions about risks, and schedules that can take over a calendar.
Caregivers become part-time project managers: coordinating infusion appointments, transportation, follow-up visits,
and MRI monitoring. The first time someone hears “you’ll need regular brain MRIs to watch for swelling,” it can land
like a punchline that isn’t funny: “Wait, the drug for Alzheimer’s can cause brain swelling?”
The practical reality is that most people who develop ARIA never feel itno headache, no dizziness, no obvious
symptomso families can’t rely on “how someone seems” to know whether swelling is present. That uncertainty can be
stressful, especially for caregivers who already carry a constant low-grade fear: “What if I miss something
important?” Many families cope by creating a simple symptom checklist on the fridge (headache, confusion beyond
baseline, vision changes, weakness, seizures), and by agreeing ahead of time on what counts as “call the clinic
today” versus “watch and wait.” It sounds small, but it gives people a sense of control in a disease that steals
control piece by piece.
Another experience that shows up again and again is the shift in family roles. A spouse who used to handle finances
may slowly hand over the checkbook. An adult child becomes the one who explains appointments and repeats the plan.
When researchers describe cellular cleanup systems (lysosomes) clogging up, it resonates metaphorically: families
feel like they’re constantly “clearing jams”in routines, communication, and safety. The most successful caregivers
aren’t superhero martyrs; they’re system builders. They simplify: fewer choices, clearer routines, predictable
environments, and gentle cues that preserve dignity.
And then there’s the grief that doesn’t wait until the end. People grieve while their loved one is still sitting at
the table. Some days are surprisingly goodlaughter, music, a familiar recipe. Other days feel like the person is
behind frosted glass. When a headline says “swelling may be the root cause,” families often interpret it as a kind
of validation: the symptoms are not laziness or stubbornness; something physical is happening inside the brain’s
wiring. That perspective can soften blame and increase compassiontwo things caregivers desperately need more of.
The most grounded families tend to hold two truths at once: today’s new drugs may help some people, especially early
on, but they are not magic. Meanwhile, emerging science on swelling and inflammation suggests tomorrow’s treatments
might target the disease from new anglesprotecting the brain’s circuits, not just cleaning up plaques. In the
meantime, families keep doing what they’ve always done: adapting, loving, repeating the plan, and finding moments of
connection wherever the signal still comes through.
Conclusion: A New Way to Think About Alzheimer’s (Without Getting Lost in the Swell)
Alzheimer’s disease is still a story of amyloid and taubut it’s also a story of what those proteins
cause downstream: inflammation, cellular traffic jams, and disrupted neural signaling. The “swelling” idea
matters because it may explain how small plaque deposits can create outsized functional problems by triggering
axonal swellings and communication breakdown.
At the same time, today’s newest anti-amyloid drugs can slow decline for some people with early Alzheimer’s, but
they require careful selection and monitoring because drug-related brain swelling (ARIA) is a real risk. If you take
one thing away, let it be this: Alzheimer’s care is moving toward a multi-tool approachbetter diagnosis, targeted
therapies, vigilant safety monitoring, and strong family support systems.
And yes, the brain is complicated. But the direction is promising: more explanations that fit what patients
experience, and more treatments that aim to preserve time, function, and connection.
